Abstracts tagged "Health care cost"

Abstract Number: 136 • 2023 Pediatric Rheumatology Symposium
Incidence and Disease Burden of Juvenile Idiopathic Arthritis and Rheumatoid Arthritis After Non-Pharmaceutical Interventions in the COVID-19 Era: A Nationwide Observational Study in Korea
Je Hee Shin¹, Jung Yoon Pyo², Minkyung Han³, Myeongjee Lee³, Sung Min Lim¹, Jee Yeon Baek¹, Ji Young Lee¹, Ji-Man Kang¹, InKyung Jung³ and Jong Gyun Ahn¹, ¹Severance Children's Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea, ²Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea, ³Department of Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul, Republic of Korea
Background/Purpose: Several countries have implemented non-pharmaceutical interventions (NPIs) against the coronavirus disease 2019 (COVID-19) pandemic. We investigated the impact of NPIs on the incidence of…
Abstract Number: 305 • 2019 ACR/ARP Annual Meeting
Naming Is Everything! the Cost of Inappropriate “Lupus Panel” Testing
Caleb Anderson¹, Roger Stitt ² and Robert O'Brian ¹, ¹Walter Reed National Military Medical Center, Bethesda, MD, ²US Army, Ft Eustis
Background/Purpose: Greater emphasis has been placed on cost saving measures due to ballooning healthcare cost in the U.S. ACGME now evaluates trainee ability to practice…
Abstract Number: 647 • 2019 ACR/ARP Annual Meeting
Is ANA-status at Disease Inception Associated with Long-term Damage Accrual and Direct and Indirect Health Care Costs in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort?
May Choi¹, Megan Barber ², Marvin Fritzler ¹, John G Hanly ³, Murray Urowitz ⁴, Yvan St-Pierre ⁵, Juanita Romero-Diaz ⁶, Caroline Gordon ⁷, Sang-Cheol Bae ⁸, Sasha Bernatsky ⁹, Daniel J Wallace ¹⁰, David A Isenberg ¹¹, Anisur Rahman ¹², Ellen M Ginzler ¹³, Michelle Petri ¹⁴, Ian Bruce ¹⁵, Paul Fortin ¹⁶, Dafna Gladman ¹⁷, Jorge Sanchez-Guerrero ¹⁸, Rosalind Ramsey-Goldman ¹⁹, Munther A Khamashta ²⁰, Cynthia Aranow ²¹, Meggan Mackay ²², Graciela Alarcón ²³, Susan Manzi ²⁴, Ola Nived ²⁵, Andreas Jönsen ²⁵, Asad Zoma ²⁶, Ronald van Vollenhoven ²⁷, Manuel Ramos-Casals ²⁸, Guillermo Ruiz-Irastorza ²⁹, S Sam Lim ³⁰, Kenneth C Kalunian ³¹, Murat Inanc ³², Diane Kamen ³³, Christine Peschken ³⁴, Soren Jacobsen ³⁵, Anca Askanase ³⁶, Vernon Farewell ³⁷ and Ann E Clarke ³⁸, ¹Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ²University of Calgary, Calgary, Canada, ³Dalhousie University, Halifax, NS, Canada, ⁴University Health Network, University of Toronto, Toronto, ON, Canada, ⁵McGill University Health Centre, Montreal, QC, Canada, ⁶Instituto Nacional de Ciencias Medicas y Nutricion Salvador, Zubiran Vasco de Quiroga, Mexico City, Mexico, ⁷University of Birmingham, Birmingham, United Kingdom, ⁸Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁹Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ¹⁰Cedars-Sinai Medical Centre, Beverly Hills, CA, ¹¹Centre for Rheumatology, London, United Kingdom, ¹²University College London, London, United Kingdom, ¹³State University of New York Downstate Medical Center, Brooklyn, NY, ¹⁴Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁵University of Manchester, Manchester, United Kingdom, Manchester, England, United Kingdom, ¹⁶Division de Rhumatologie, Département de Médecine, CHU de Québec – Université Laval, Axe maladies infectieuses et inflammatoires, Centre de recherche du CHU de Québec – Université Laval, Canada, Quebec, QC, Canada, ¹⁷University of Toronto, Toronto, ON, Canada, ¹⁸Toronto Western Hospital, Toronto, ON, Canada, ¹⁹Northwestern University, Chicago, IL, ²⁰King's College London School of Medicine, London, United Kingdom, ²¹Feinstein Institute for Medical Research, Manhasset, NY, ²²Feinstein Institute for Medical Research, New York, ²³University of Alabama at Birmingham, Birmingham, ²⁴Allegheny Health Network, Pittsburg, PA, ²⁵Lund University, Lund, Sweden, ²⁶Hairmyres Hospital, East Kilbride, United Kingdom, ²⁷Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, the Netherlands, Amsterdam, Netherlands, ²⁸Josep Font Autoimmune Diseases Laboratory, Barcelona, Spain, ²⁹Autoimmune Diseases Unit, Hospital Universitario Cruces, Barakaldo, Spain, Barakaldo, Spain, ³⁰Emory University, Atlanta, GA, ³¹UC San Diego School of Medicine, LaJolla, CA, ³²Istanbul University, Istanbul, Turkey, ³³Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA., Charleston, SC, ³⁴University of Manitoba, Winnipeg, Canada, ³⁵Copenhagen Lupus and Vasculitis Clinic, Copenhagen, Denmark, ³⁶Columbia University Medical Center, New York, NY, ³⁷University of Cambridge, Cambridge, United Kingdom, ³⁸University of Calgary, Calgary, AB, Canada
Background/Purpose: We reported that 7.7% (88/1137) of patients in an international inception cohort were ANA-negative at enrolment (Arthritis Care Res 2018 doi:1002/acr23712). There are no…
Abstract Number: 1801 • 2019 ACR/ARP Annual Meeting
Comparison of Infection-Related Hospitalization Risk and Cost in TNFi-Experienced Medicare Beneficiaries with Rheumatoid Arthritis Treated with Abatacept or Other Targeted Disease-Modifying Anti-Rheumatic Drugs
Vardhaman Patel¹, Zulkarnain Pulungan ², Anne Shah ², Mahesh Kambhampati ², Francis Lobo ³ and Allison Petrilla ², ¹Bristol-Myers Squibb, New York City, NY, ²Avalere, washington, DC, ³Bristol-Myers Squibb Company, Princeton, NJ
Background/Purpose: The risk and cost of infection-related hospitalizations in tumor necrosis factor inhibitors (TNFi)-experienced patients with rheumatoid arthritis (RA) receiving subsequent targeted disease-modifying antirheumatic drug…
Abstract Number: 2677 • 2019 ACR/ARP Annual Meeting
Healthcare Resources Utilization in Giant Cell Arteritis – a Population-Based Study
Aladdin Mohammad¹, Aleksandra Turkiewicz ², Pavlos Stamatis ¹, Carl Turesson ³, Martin Englund ² and Ali Kiadaliri ², ¹Lund University, Lund, Skane Lan, Sweden, ²Lund University, Lund, Sweden, ³Lund University, Malmö, Sweden
Background/Purpose: To study the healthcare resource utilization (HRU) in patients with giant cell arteritis (GCA) compared with the background population in southern Sweden.Methods: The study…
Abstract Number: 2889 • 2019 ACR/ARP Annual Meeting
From a Potential Solution to Part of the Problem: Analysis of Spending and Price Trends for Brand-Name and Generic Colchicine and Other Gout Medications
Natalie McCormick¹, Zachary Wallace ², Chio Yokose ³, April Jorge ³, Chana Sacks ⁴, John Hsu ⁵ and Hyon K. Choi ³, ¹Massachusetts General Hospital and Harvard Medical School, Boston, MA, ²Massachusetts General Hospital, Boston, ³Massachusetts General Hospital, Boston, MA, ⁴Department of General Internal Medicine, Massachusetts General Hospital; Department of Medicine, Harvard Medical School, Boston, MA, ⁵Mongan Institute, Massachusetts General Hospital; Department of Health Care Policy, Harvard Medical School, Boston, MA
Background/Purpose: Gout affects >4 million US adults aged ≥ 65 years, but little is known about the scale and drivers of public spending on gout…
Abstract Number: 859 • 2018 ACR/ARHP Annual Meeting
Using Online Simulation of Pediatric Musculoskeletal Cases to Evaluate How Knowledge of Costs Affects Diagnostic Workup
Allison Yip¹, Simrat Morris², Marc Buchner³ and Angela Robinson⁴, ¹School of Medicine, Case Western Reserve University, Cleveland, OH, ²Rainbow Babies & Children's Hospital / Cleveland Medical Center, Cleveland, OH, ³School of Engineering, Case Western Reserve University, Cleveland, OH, ⁴Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: With rapid rise in healthcare costs, there is increased emphasis to teach cost-conscious care in graduate medical education. Our objective was to develop online…
Abstract Number: 1264 • 2018 ACR/ARHP Annual Meeting
Modeling the Costs and Outcomes Associated with Treatment Sequences, with and without Tofacitinib, for Moderately to Severely Active Psoriatic Arthritis in the US
George Bungey¹, Stacey Chang-Douglass¹, Ming-Ann Hsu², Joseph C Cappelleri², Pamela Young³ and John Woolcott³, ¹Decision Resources Group, London, United Kingdom, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, Collegeville, PA
Background/Purpose: Psoriatic Arthritis (PsA) is a chronic progressive inflammatory condition associated with significant direct and indirect costs. Tofacitinib is an oral Janus kinase inhibitor for…
Abstract Number: 2595 • 2018 ACR/ARHP Annual Meeting
Golimumab Improves Socio- and Health Economic Parameters in Patients with RA, Psa and As: Real World-Data from a Non-Interventional Clinical Study in Germany
Klaus Krüger¹, Gerd R. Burmester², Siegfried Wassenberg³, Valeria Biermann⁴ and Matthias H. Thomas⁵, ¹Medical Centre of Rheumatology, Munich, Germany, ²Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Berlin, Germany, ³Rheumazentrum Ratingen, Ratingen, Germany, ⁴Lehrstuhl für Gesundheitsmanagement, Universität Erlangen-Nürnberg, Nürnberg, Germany, ⁵Medical Affairs, MSD Sharp & Dohme GmbH, Haar, Germany
Background/Purpose: Golimumab (GLM) has shown its efficacy and safety in various clinical trials. Data from socio- and health economic parameters and costs in daily clinical…
Abstract Number: 2724 • 2018 ACR/ARHP Annual Meeting
Variable Response to Induction Therapy and Significant Burden of Treatment Adverse Events over the First 12 Months in Incident ANCA-Associated Vasculitis (AAV) Patients – a Study of Routine Clinical Practice in the EU
Peter Rutherford¹, Dieter Goette¹, Melinda Stamm² and Xierong Liu², ¹Medical Affairs, Vifor Pharma, Zurich, Switzerland, ²Elma Research, London, United Kingdom
Background/Purpose: Aims of therapy in incident AAV patients include ensuring rapid diagnosis, assessment of comorbidity, disease activity, and vasculitis damage before commencing treatment with a…
Abstract Number: 1054 • 2017 ACR/ARHP Annual Meeting
Healthcare Utilization Profiles in Rheumatoid Arthritis – a Cluster Analysis
Nina Mars^1,2, Anne M Kerola^2,3, Markku J Kauppi^4,5, Matti Pirinen¹, Outi Elonheimo⁶ and Tuulikki Sokka-Isler⁷, ¹Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland, ²University of Helsinki, Helsinki, Finland, ³Department of Internal Medicine, Päijät-Häme Central Hospital, Lahti, Finland, ⁴School of Medicine, University of Tampere, Tampere, Finland, ⁵Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland, ⁶FCG Finnish Consulting Group Ltd., Helsinki, Finland, ⁷Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland
Background/Purpose: Utilization patterns in rheumatoid arthritis (RA) are complex. For targeted interventions, patients with special healthcare needs should be recognized. Our aim was to explore…
Abstract Number: 1561 • 2017 ACR/ARHP Annual Meeting
Network Meta-Analysis of Targeted Immunomodulators in the Treatment of Biologic-NaïVe Psoriatic Arthritis
Vibeke Strand¹, M. Elaine Husni², Rakesh Singh³, Keith Betts⁴, Yan Song⁵, Jenny Griffith³ and Arijit Ganguli³, ¹Stanford University, Palo Alto, CA, ²Cleveland Clinic, Cleveland, OH, ³AbbVie Inc., North Chicago, IL, ⁴Analysis Group, Inc., Los Angeles, CA, ⁵Analysis Group, Inc., Boston, MA
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory condition characterized by peripheral arthritis and psoriatic skin lesions requiring therapies that control both skin and joint symptoms.…
Abstract Number: 2260 • 2017 ACR/ARHP Annual Meeting
Communication Strategies Are Highly Important to Avoid Nocebo Effect When Performing Non-Medical Switch from Originator Product to Biosimilar Product: Danish Results from Applying the Parker Model a Qualitative 3-Step Research Model
Tanja Schjødt Jørgensen¹, Marie Skougaard¹, Hans Christian Asmussen^2,3, Anne Lee⁴, Peter C. Taylor⁵, Henrik Gudbergsen¹ and Lars Erik Kristensen¹, ¹The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen F, Denmark, ²NATiON, Copenhagen, Denmark, ³Communication IKH, Roskilde University, Roskilde, Denmark, ⁴University of Southern Denmark, Odense, Denmark, ⁵University of Oxford Botnar Research Centre, Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom
Background/Purpose: Introducing a non-medical switch from originator to a biosimilar product in the management of chronic arthritis, i.e. switching patients in remission or low disease…
Abstract Number: 2812 • 2017 ACR/ARHP Annual Meeting
Healthcare Resource Utilization and Costs in Patients with Systemic Lupus Erythematosus before and after Initiating Treatment with Intravenous Belimumab: A US Claims Database Analysis
Christopher F Bell¹, Julie Priest^2,3, Marni Stott-Miller⁴, Hong Kan⁵, Justyna Amelio⁶, Xue Song⁷, Brendan Limone⁷, Virginia Noxon⁷ and Karen H. Costenbader⁸, ¹GSK US Value, Evidence and Outcomes, Research Triangle Park, NC, ²GSK US Value, Evidence and Outcomes (at the time of Study)*, Research Triangle Park, NC, ³US Health Outcomes Durham, *ViiV Healthcare (Present), Durham, NC, ⁴GSK Real World Evidence & Epidemiology, Uxbridge, United Kingdom, ⁵Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ⁶GSK Real World Evidence & Epidemiology, Stevenage, United Kingdom, ⁷Truven Health Analytics, an IBM company, Ann Arbor, MI, ⁸Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Belimumab, an inhibitor of B lymphocyte stimulator, is approved in adults with active, autoantibody-positive systemic lupus erythematosus (SLE) receiving standard of care. There is…
Abstract Number: 2831 • 2017 ACR/ARHP Annual Meeting
Real-World Experience with Tofacitinib Versus Adalimumab and Etanercept in Biologic-Naive Patients with RA Previously Treated with Methotrexate: Data from a US Administrative Healthcare Insurance Claims Database
Tim Smith¹, James Harnett¹, David Gruben², Connie Chen¹, Ekta Agarwal¹ and John Woolcott³, ¹Pfizer Inc, New York, NY, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Tofacitinib access has been restricted by many US payers to use after…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].